Table 1.
Marker
|
Definition
|
Expressed on cells
|
Addition
|
Types of cancer
|
Ref.
|
PROX-1 | An evolutionarily conserved class of atypical homeodomain proteins | LECs | Located in the nucleus and promoting lymphangiogenesis | Breast cancer; Melanoma; Glioblastoma | [50-56] |
PDPN | A transmembrane mucin type O-glycoprotein | LECs | Functioning in the downstream of PROX-1 | Angiosarcomas;Melanoma; Colorectal carcinoma; Breast cancer; Osteosarcoma | [57-60] |
LYVE-1 | One of the hyaluronan-binding glyco-protein receptors | LECs | Acting with VEGFR and PDGFR in the LECs | Oral oncogenesis; Lung cancer | [62-66] |
VEGFR-3 | An receptor tyrosine kinase | LECs/BECs | Functioning by activating RAS/RAF-1/MEK/ERK signaling pathway | Gastric cancer; Intrahepatic cholangiocarcinoma; Colorectal carcinoma | [67,68] |
CD31 | One of the immunoglobulin superfamily | LECs/BECs | Promoting tumor angiogenesis by regulating TME indirectly | Breast cancer; Melanoma; Gastric cancer | [71,73-75] |
CD105 | Homodimeric transmembrane glycoprotein, a coreceptor for ligands of the TGF-β family | BECs | Also called Endoglin | Esophageal squamous cell carcinoma; Colorectal carcinoma | [76-79] |
BECs: Blood endothelial cells; LECs: Lymphatic endothelial cells; LYVE-1: Lymphatic vessel endothelial hyaluronan receptor 1; PDGFR: Platelet-derived growth factor receptor; PDPN: Podoplanin; PROX-1: Prospero homeobox 1; VEGFR: Vascular endothelial growth factor receptor; TME: Tumor microenvironment.